Patents by Inventor Peter ULRICHTS

Peter ULRICHTS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FCRN Antagonists and Methods of Use
    Publication number: 20150218239
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Application
    Filed: December 23, 2014
    Publication date: August 6, 2015
    Applicants: arGEN-X B.V., The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • CHIMERIC HUMAN-LLAMA ANTIGENS AND METHODS OF USE
    Publication number: 20140286976
    Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.
    Type: Application
    Filed: November 5, 2012
    Publication date: September 25, 2014
    Applicant: arGEN-X B.V.
    Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier
  • Antibodies to CD70
    Patent number: 8834882
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 16, 2014
    Assignee: arGEN-X B.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • ANTIBODIES TO CD70
    Publication number: 20140235843
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: January 24, 2014
    Publication date: August 21, 2014
    Applicant: arGEN-X B.V.
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • ANTIBODIES TO CD70
    Publication number: 20140147450
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 29, 2014
    Applicant: ARGEN-X B.V.
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR